SEC Form 4 · accession 0000905148-26-004085
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian N Cherry
Director
Period of report
Sep 4, 2026
Accepted (ET)
Sep 4, 2026 · 6:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 4, 2026 | P | 104,166 | $9.60 | A | 166,486 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares purchased by the Reporting Person from the Issuer, through its sales agent, pursuant to that certain Sales Agreement, dated November 1, 2023, by and between the Issuer and TD Securities (USA) LLC.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney